Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-Associated Lipodystrophy Syndrome

Interventions

DRUG: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)
DRUG: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)

Sponsor

Bristol-Myers Squibb